1. Home
  2. HALO vs G Comparison

HALO vs G Comparison

Compare HALO & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HALO
  • G
  • Stock Information
  • Founded
  • HALO 1998
  • G 1997
  • Country
  • HALO United States
  • G Bermuda
  • Employees
  • HALO N/A
  • G N/A
  • Industry
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • G Professional Services
  • Sector
  • HALO Health Care
  • G Consumer Discretionary
  • Exchange
  • HALO Nasdaq
  • G Nasdaq
  • Market Cap
  • HALO 7.6B
  • G 7.2B
  • IPO Year
  • HALO N/A
  • G 2007
  • Fundamental
  • Price
  • HALO $66.96
  • G $39.48
  • Analyst Decision
  • HALO Buy
  • G Buy
  • Analyst Count
  • HALO 11
  • G 7
  • Target Price
  • HALO $73.09
  • G $50.14
  • AVG Volume (30 Days)
  • HALO 2.2M
  • G 1.7M
  • Earning Date
  • HALO 11-04-2025
  • G 11-06-2025
  • Dividend Yield
  • HALO N/A
  • G 1.72%
  • EPS Growth
  • HALO 68.93
  • G N/A
  • EPS
  • HALO 4.37
  • G 3.01
  • Revenue
  • HALO $1,178,672,000.00
  • G $4,929,034,000.00
  • Revenue This Year
  • HALO $32.57
  • G $7.51
  • Revenue Next Year
  • HALO $23.77
  • G $6.69
  • P/E Ratio
  • HALO $15.35
  • G $13.10
  • Revenue Growth
  • HALO 34.97
  • G 7.40
  • 52 Week Low
  • HALO $42.01
  • G $37.82
  • 52 Week High
  • HALO $79.50
  • G $56.76
  • Technical
  • Relative Strength Index (RSI)
  • HALO 41.47
  • G 35.25
  • Support Level
  • HALO $63.80
  • G $38.22
  • Resistance Level
  • HALO $68.00
  • G $39.92
  • Average True Range (ATR)
  • HALO 2.30
  • G 0.82
  • MACD
  • HALO -0.48
  • G -0.10
  • Stochastic Oscillator
  • HALO 25.24
  • G 32.10

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About G Genpact Limited

Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.

Share on Social Networks: